Cytokinetics CYTK License — Revenue
Discontinued — last reported Q4 '23
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Cytokinetics in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Cytokinetics’s 10-K, filed February 28, 2024, on SEC EDGAR. View the filing →
Ask your AI about Cytokinetics's license — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Cytokinetics's license — revenue?
- Cytokinetics (CYTK) reported license — revenue of $0 in Q4 2023.
- What is the long-term trend for Cytokinetics's license — revenue?
- Over 2 years (2021 to 2023), Cytokinetics's license — revenue has grown at a -100.0% compound annual growth rate (CAGR), from $54.9M to $0.
- What does license — revenue mean?
- Revenue earned from granting other companies the rights to use or develop the company's proprietary technology or drug candidates.
- How do you interpret license — revenue?
- An increase indicates successful commercialization of research assets or the achievement of development milestones, while a decrease suggests a lack of new partnership activity or the conclusion of existing licensing agreements.
- How does license — revenue compare across companies?
- Biotechnology peers often report this as 'License and Collaboration Revenue,' which is typically characterized by lumpy, non-recurring cash flows tied to specific clinical or regulatory events.